Prostate Cancer Blog

ASCO 2014: Combining Advanced Hormone Therapies (Zytiga & Xtandi) Shows Promise for Men with Advanced Prostate Cancer

In my continuing reports about interesting and pertinent information released at the ASCO 2014 meeting one abstract described a phase 2 trial combining an attack on androgens in metastatic prostate cancer resistant to initial hormone therapy. This proof of concept study showed that combining Enzalutamide (Xtandi) plus abiraterone (Zytiga) drove down testosterone levels and appeared [...]

By Malecare|2017-10-19T10:48:10-04:00June 5th, 2014|2nd line hormone therapy, abiraterone acetate, ADT, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, Uncategorized, Xtandi, Zytiga|1 Comment

ASCO 2014 – ADT May Be Deferred After A Bio-Chemical (PSA only) Relapse in Men with Prostate Cancer

Current practice has been to immediately begin hormone therapy (ADT) as soon as a man has a bio-chemical (PSA only) relapse. A recent presentation at ASCO 2014 has shown that immediate ADT actually offers little or no survival benefit over deferred ADT to advanced prostate cancer survivors who experience a PSA only relapse after radical [...]

By Malecare|2014-06-04T10:16:56-04:00June 4th, 2014|ADT, Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Drugs & Treatments, PSA, Research, Uncategorized, Understanding APC|0 Comments

The ASCO 2014 Game Changer – Early Chemotherapy for Some Men Extends Survival

I was asked if there was one item that was a real game changer at the American Society of Clinical Oncologists (ASCO) meeting for men with advanced prostate cancer. The answer is yes, at this meeting it was formally shown by a study that starting chemotherapy (docetaxel) along with androgen deprivation therapy (ADT) in some [...]

By Malecare|2014-06-03T10:23:15-04:00June 3rd, 2014|ADT, Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, Uncategorized, Understanding APC|4 Comments

ASCO 2014 – Where the Tumors Are Located Influences Survival

ASCO has become a little more interesting for prostate cancer. Today's item is about a mega-analysis that confirms that the site of metastatic tumors will powerfully predict overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC). Older and smaller studies had previously suggested that the metastatic site is prognostic for OS. This [...]

By Malecare|2014-06-02T23:10:17-04:00June 2nd, 2014|Advanced Prostate Cancer, Bone Metastases, Metastases, Uncategorized, Understanding APC|0 Comments

From ASCO – Early Radiation Might Increase Survival

I have been at American Association of Clinical Oncologists (ASCO) since last Thursday. On the prostate cancer front the most exciting part of the meeting has been our being in Chicago and that the weather which has been fantastic. The only truly newsworthy thing that I have come across so far has been an abstract [...]

By Malecare|2020-02-04T08:41:39-05:00May 31st, 2014|adjuvant therapy, ADT, Advanced Prostate Cancer, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments

Denosumab is Superior to Zoledronic Acid (ZA) for Pain Interference and Quality of Life

Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will eventually develop debilitating pain that impacts daily functioning and diminishes their quality of life. Based on prior studies, including a phase III trial, the superiority of denosumab over zoledronic acid (ZA) in delaying or preventing skeletal-related events (pathological fracture, radiation or surgery to the [...]

By Malecare|2020-02-04T10:22:05-05:00May 27th, 2014|Advanced Prostate Cancer, Bone Health, Bone Metastases, denosumab - Xgeva, Drugs & Treatments, Quality of Life, Uncategorized, Understanding APC, Zometa|0 Comments

Is there a Need to Rush to Treatment when you Experience a Biochemical (PSA only) Prostate Cancer Recurrence?

As usual, we are confronted with a new contradiction. It has been believed that earl hormone therapy (ADT) in men with a biochemical recurrence (PSA only) would benefit from immediate ADT. A study released from the Harvard School of Public Health contradicts this assumption, but the study lacks follow up beyond 10 years. They evaluated [...]

By Malecare|2017-10-19T10:48:16-04:00May 23rd, 2014|ADT, Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Drugs & Treatments, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments

Does Prior Response to Zytiga Affect Subsequent Activity of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)?

Given all the newly approved drugs available to us to treat advanced prostate cancer there now are many questions about the optimal sequencing of these drugs and whether earlier use of one causes cross-resistance to another. Recently, it was reported that chemotherapy with docetaxel is inactive in men with metastatic castrate resistant prostate cancer (mCRPC) [...]

By Malecare|2017-10-19T10:48:19-04:00May 21st, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Cross Resistance, Drugs & Treatments, Research, Uncategorized, Understanding APC, Zytiga|0 Comments

Which Men are at the Greatest Risk of Weight Gain on Hormone Therapy? Knowing Your Risk Factors

Androgen deprivation therapy (ADT) is the most common first therapy for men diagnosed with metastatic prostate cancer as well as many men with non-metastatic prostate cancer. ADT brings with it many side effects including significant weight gain. Weight gain, which may contribute to cardiovascular comorbidities as well as diabetes, is among the many adverse metabolic [...]

By Malecare|2017-10-19T10:48:20-04:00May 20th, 2014|ADT, Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, Uncategorized, weight gain|0 Comments

Preliminary Data Released for A Phase II Trial of Sipuleucel-T (Provenge) with Concurrent or Sequential Enzalutamide (Xtandi) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

There will be an abstract presented at the Upcoming (May 31- June 3) American Society of Clinical Oncologist Annual Meeting (ASCO) providing very preliminary data on a clinical trial combing Sipuleucel-T (Provenge) and enzalutamide (Xtandi) in men with metastatic castrate resistant prostate cancer (mCRPC). This rational for conducting this trial is the lack of cross [...]

By Malecare|2020-02-04T10:12:06-05:00May 16th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, enzalutamide, immunotherapy, Provenge, Uncategorized, vaccines, Xtandi|0 Comments